“Pompe Disease Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pompe Disease Market.
The Pompe Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Pompe Disease Pipeline Report:
Companies across the globe are diligently working toward developing novel Pompe Disease treatment therapies with a considerable amount of success over the years. Pompe Disease Key players such as – Asklepios Biopharmaceutical, GeneCradle Inc, Astellas Gene Therapies, Amicus Therapeutics, M6P Therapeutics, Entrada Therapeutics, Maze Therapeutics, Astellas Gene Therapies, Spark Therapeutics, and others, are developing therapies for the Pompe Disease treatment
Pompe Disease Emerging therapies such as – ACTUS-101, GC301, zocaglusagene nuzaparvovec, AT2221, M 021, GYS1 Knockdown Oligonucleotide, MZE 001, AT845, AAV2/8LSPhGAA, SPK-3006, Cipaglucosidase alfa, and others are expected to have a significant impact on the Pompe Disease market in the coming years.
In May 2024, Shionogi & Co., Ltd. (Osaka, Japan; CEO: Isao Teshirogi, Ph.D.) and Maze Therapeutics, Inc. (South San Francisco, California, USA; CEO: Jason Coloma, Ph.D.) have announced the completion of an exclusive global licensing agreement for MZE001. MZE001 is an investigational oral glycogen synthase 1 (GYS1) inhibitor designed to address Pompe disease by reducing the buildup of disease-causing glycogen.
In November 2023, Aro Biotherapeutics, a clinical-stage biotech company, has secured $41.5 million in a Series B funding round to further develop its lead candidate, ABX1100, for the treatment of Pompe disease. The round was led by Cowen Healthcare Investments, with participation from Series A investors including Northpond Ventures, Johnson & Johnson Innovation – JJDC, BVF Partners, and HealthCap.
Pompe Disease Overview
Pompe disease belongs to the ‘lysosomal storage disorders’ (LSDs) group of diseases. Within the cells, lysosomes are tiny compartments where all sorts of substances are recycled. By the action of digestive enzymes, the compounds are degraded. There are currently more than 50 different LSDs that are considered to be caused by the deficiency of one of these enzymes.
Get a Free Sample PDF Report to know more about Pompe Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/pompe-disease-pipeline-insight
Route of Administration
Pompe Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Molecule Type
Products have been categorized under various Molecule types, such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Pompe Disease Pipeline Therapeutics Assessment
Pompe Disease Assessment by Product Type
Pompe Disease By Stage and Product Type
Pompe Disease Assessment by Route of Administration
Pompe Disease By Stage and Route of Administration
Pompe Disease Assessment by Molecule Type
Pompe Disease by Stage and Molecule Type
DelveInsight’s Pompe Disease Report covers around 20+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Some of the key companies in the Pompe Disease Therapeutics Market include:
Key companies developing therapies for Pompe Disease are – Spark Therapeutics, Amicus Therapeutics, Asklepios Biopharmaceutical, Audentes Therapeutics, Rocket Pharmaceuticals, Avidity Biosciences, AVROBIO, Maze Therapeutics, Denali Therapeutics, and others.
Emerging Pompe Disease Drugs Under Different Phases of Clinical Development Include:
ACTUS-101: Asklepios Biopharmaceutical
GC301: GeneCradle Inc
zocaglusagene nuzaparvovec: Astellas Gene Therapies
AT2221: Amicus Therapeutics
M 021: M6P Therapeutics
GYS1 Knockdown Oligonucleotide: Entrada Therapeutics
MZE 001: Maze Therapeutics
AT845: Astellas Gene Therapies
AAV2/8LSPhGAA: Asklepios Biopharmaceutical
SPK-3006: Spark Therapeutics
Cipaglucosidase alfa: Amicus Therapeutics
Download Sample PDF Report to know more about Pompe Disease drugs and therapies
Pompe Disease Pipeline Analysis:
The Pompe Disease pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Pompe Disease with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pompe Disease Treatment.
Pompe Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Pompe Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pompe Disease market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Pompe Disease product details are provided in the report. Download the Pompe Disease pipeline report to learn more about the emerging Pompe Disease therapies
Pompe Disease Pipeline Market Drivers
Improving Healthcare Infrastructure
Demand for New and Effective Drugs
Increasing research and development in the gene therapy and enzyme replacement therapy areas
Pompe Disease Pipeline Market Barriers
Lack Of Cost-Effective Treatment
Scope of Pompe Disease Pipeline Drug Insight
Coverage: Global
Key Pompe Disease Companies: Asklepios Biopharmaceutical, GeneCradle Inc, Astellas Gene Therapies, Amicus Therapeutics, M6P Therapeutics, Entrada Therapeutics, Maze Therapeutics, Astellas Gene Therapies, Spark Therapeutics, and others
Key Pompe Disease Therapies: ACTUS-101, GC301, zocaglusagene nuzaparvovec, AT2221, M 021, GYS1 Knockdown Oligonucleotide, MZE 001, AT845, AAV2/8LSPhGAA, SPK-3006, Cipaglucosidase alfa, and others
Pompe Disease Therapeutic Assessment: Pompe Disease current marketed and Pompe Disease emerging therapies
Pompe Disease Market Dynamics: Pompe Disease market drivers and Pompe Disease market barriers
Request for Sample PDF Report for Pompe Disease Pipeline Assessment and clinical trials
Table of Contents
1
Pompe Disease Report Introduction
2
Pompe Disease Executive Summary
3
4
Pompe Disease- Analytical Perspective In-depth Commercial Assessment
5
Pompe Disease Pipeline Therapeutics
6
Pompe Disease Late Stage Products (Phase II/III)
7
Pompe Disease Mid Stage Products (Phase II)
8
Pompe Disease Early Stage Products (Phase I)
9
Pompe Disease Preclinical Stage Products
10
Pompe Disease Therapeutics Assessment
11
Pompe Disease Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
Pompe Disease Key Companies
14
Pompe Disease Key Products
15
Pompe Disease Unmet Needs
16
Pompe Disease Market Drivers and Barriers
17
Pompe Disease Future Perspectives and Conclusion
18
Pompe Disease Analyst Views
19
Appendix
20
About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las vegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
